High throughput screening (HTS) process carries out the assessment of small molecule compound libraries for binding, activating or inactivating biological activity in drug target molecules to rapidly identify the compounds with desired therapeutic activity. High Throughput Screening Technology has been playing a crucial role in the enhancement of drug discovery process and regenerative medicine areas. Therefore, the pharmaceuticals & biotechnology industries are adopting HTS as routine technology for the reduction of drug development cost through reduced drug discovery duration and drug failure rate. “Meticulous Research” in its latest publication states that, the “global market for high throughput screening is expected to grow at a CAGR of 8.0% from 2017 to 2022 to reach $21,911.1 million by 2022.”
This growth is primarily driven by the increasing adoption of innovative approaches in pharmaceutical and biotechnology companies, increasing investment by private equity firms and venture capitalists, rising government funding for R&D, increasing healthcare spending, and various technological advancements.
Biopharmaceutical drug development has been experiencing one of its most productive periods in recent years. During the past decade, the total number of new chemical and biologic entities in the R&D pipeline has been rising by around 6% each year and now exceeds 10,000 active drug candidates targeting unmet and under-served medical needs. The average cost to research and development of each successful drug is estimated to be $2.6 billion. A variety of discovery technologies have helped driving the growth of drug development pipeline. The high-throughput screening has resulted in a tenfold reduction in the cost of testing compound libraries; and combinatorial chemistry has increased 800-fold the number of new molecular entities to be potentially synthesized.
According to the PhRMA, total spending on biopharmaceutical R&D was $140 billion in 2014 worldwide, representing a 4.9% compound annual growth rate during the past ten years. According to the FDA’s Center for Drug Evaluation and Research (CDER), around 45 novel drugs approved as new molecular entities under New Drug Application in the year 2015. From 2006 to 2014, CDER averagely approved 28 novel drugs per year. CDER identified 16 of the 45 novel drugs approved in 2015 as first in class due to innovative techniques of drug discovery. The phenotypic screening strategy accounted more than target based approach which has resulted in the growing adoption of high throughput screening techniques.
The drug discovery and development procedure is highly expensive and time consuming. The major factor in the process is clinical trials phases which cost major expense in the process. The rate of failure in drug discovery is very less, as less than 12% of candidate medicine present in clinical trials make it to FDA approval. The biopharmaceutical industry accounts for the vast majority of investment into clinical trials and related activities; in 2013, biopharmaceutical companies sponsored 6,199 trials across the U.S. involving 1.1 million participants.
To improve the efficiency of drug development procedure, innovative approaches such as use of biomarkers to identify appropriate diseases and their target area that may respond to a therapy are recently used by biopharmaceutical and biotechnological industries. This has helped the pharmaceutical and biotechnology organizations to widely adopt these approaches in high throughput screening by discovering innovative products that serves unmet medical needs or otherwise significantly help to advance patient care and public health. Thereby, the increasing adoption of such innovative approaches may drive the growth of high throughput screening market in near future.
High Throughput Screening Market Size by Products & Services (Consumables & Reagents, Instruments, Software & Services), by Application (Stem Cell Research, Toxicology Assessment, Primary Screening, Target Identification), by End-User (Pharmaceuticals and Biotechnology Industries, Academics and Research Institutes, Contract Research Organizations, and Others) – Global Opportunity Analysis and Industry Forecasts To 2022
For detailed Table of Content, Download free sample report here: https://www.meticulousresearch.com/download-sample-report/?cp_id=3206
The key players analyzed in the high throughput screening market report are Merck KGaA (Germany), Charles River Laboratories International, Inc. (U.S.), AXXAM S.p.A. (Italy), Thermo Fisher Scientific Inc. (U.S.), Danaher Corporation (U.S.), Perkin Elmer (U.S.), Agilent technologies, Inc. (U.S.), Bio-Rad Laboratories, Inc.(U.S.), Tecan Trading AG (Switzerland), Aurora Biomed, Inc. (Canada), and Hamilton Company (U.S.).